Effect of 1-year cholecalciferol supplementation from early post-transplant preiod in kidney transplant recipients: a randomized controlled trial

Effect of 1-year cholecalciferol supplementation from early post-transplant preiod in kidney transplant recipients: a randomized controlled trial - Cholecalciferol supplementation from early period of kidney transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020597

Enrollment

200

Registered

2016-01-17

Start date

2016-01-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

kidney transplantation

Interventions

Oral Cholecalciferol 1 capsule containing 4000 IU/day Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. eGFR >= 30 ml/min/1.73m2 2. <1 month after kidney transplantation 3. With written informed concent 4. Living kidney transplant recipients at Nagoya Red Cross Hospital

Exclusion criteria

Exclusion criteria: 1. On supplementation with native vitamin D (i.e., cholecalciferiol or ergocaliferol) 2. Corrected calcium >= 11.0 mg/dL 3. Patients judged to be inappropriate by the physician in charge

Design outcomes

Primary

Measure	Time frame
Change in estimated glomerular filtration rate at 1 year after KTx with adjustment for baseline values	—

Secondary

Measure	Time frame
1. Urinary kidney injury biomarkers (i.e., L-FABP and/or urinary protein/creatinine) at 6 months and 12 months after KTx 2. Pathophysiological findings on transplanted kidney at 12 months after KTx 3. Body compositions at 6 months and 12 months after transplantation 4. Bone metabolic markers and bone mineral density at 12 months after KTx 5. Prevalence of the development of hypercalcemia (corrected serum calcium>=11mg/dL) 6. Hospitalization-requiring infection-free survival	—

Measure

Time frame

1. Urinary kidney injury biomarkers (i.e., L-FABP and/or urinary protein/creatinine) at 6 months and 12 months after KTx 2. Pathophysiological findings on transplanted kidney at 12 months after KTx 3. Body compositions at 6 months and 12 months after transplantation 4. Bone metabolic markers and bone mineral density at 12 months after KTx 5. Prevalence of the development of hypercalcemia (corrected serum calcium>=11mg/dL) 6. Hospitalization-requiring infection-free survival

—

Countries

Japan

Contacts

Public ContactMakoto Tsujita

Nagoya Daini Red Cross Hospital Transplant Surgery

tsujita4850@yahoo.co.jp052-832-1121

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026